Insiders · BIOA

BIOA insider transactions

BioAge Labs Inc. (BIOA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

BIOA insiders

Everyone who has filed a Form 3, 4, 5 or 144 at BioAge Labs Inc., latest first. Follow anyone to get their next filing.

• Shane BartonPrincipal Accounting Officer+$47.4K-$1.58M
• Vijay Satyanand PandeDirector+$20.5M
• Rekha HemrajaniDirector+$54K
• James HealyDirector+$12M
• Patrick G EnrightDirector+$7.2M
• Michael H. DavidsonDirector
• Jean Pierre GarnierDirector
• Goldstein Dov A MdChief Financial Officer-$532K
• Paul D RubinChief Medical Officer-$1.46M
• Eric MorgenChief Operating Officer, Director
• Kristen FortneyChief Executive Officer, Director-$4.22M
• Cormorant Asset Management, LPFormer 10% Owner+$8.1M

Recent Form 3, 4, and 5 filings for BIOA

• 131d
  Principal Accounting Officer Barton Shane exercised 59,934 shares at a strike of $6.58 and sold $1,576,752 worth of shares (62,566 units at $25.20) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Pande Vijay Satyanand

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Hemrajani Rekha

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Healy James

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Enright Patrick G

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Davidson Michael H.

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 150d
  SEC Form 4 filed by Director Garnier Jean Pierre

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 199d
  Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 220d
  SEC Form 4 filed by Rubin Paul D

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 251d
  Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $150,890 worth of shares (7,433 units at $20.30) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 251d
  Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 12% to 33,033 units (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 263d
  SEC Form 4 filed by Chief Medical Officer Rubin Paul D

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 263d
  SEC Form 4 filed by Chief Operating Officer Morgen Eric

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 263d
  SEC Form 4 filed by Chief Financial Officer Goldstein Dov A Md

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 263d
  SEC Form 4 filed by Chief Executive Officer Fortney Kristen

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 263d
  SEC Form 4 filed by Principal Accounting Officer Barton Shane

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 279d
  Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $139,369 worth of shares (7,433 units at $18.75) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 279d
  Chief Financial Officer Goldstein Dov A Md exercised 3,541 shares at a strike of $4.38, increasing direct ownership by 14% to 29,491 units (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 292d
  Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 16% to 25,950 units (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 298d
  Chief Financial Officer Goldstein Dov A Md exercised 27,000 shares at a strike of $8.39 and sold $531,828 worth of shares (27,000 units at $19.70) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 298d
  Chief Executive Officer Fortney Kristen sold $4,223,036 worth of shares (233,107 units at $18.12), decreasing direct ownership by 19% to 976,949 units (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 307d
  Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $95,490 worth of shares (7,433 units at $12.85) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 333d
  Chief Medical Officer Rubin Paul D exercised 18,000 shares at a strike of $6.57 and sold $216,000 worth of shares (18,000 units at $12.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 338d
  Chief Medical Officer Rubin Paul D exercised 68,897 shares at a strike of $4.11 and sold $701,909 worth of shares (68,897 units at $10.19) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 455d
  SEC Form 4 filed by Director Pande Vijay Satyanand

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 518d
  SEC Form 4 filed by Director Hemrajani Rekha

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 518d
  SEC Form 4 filed by Director Healy James

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 518d
  SEC Form 4 filed by Director Enright Patrick G

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 518d
  SEC Form 4 filed by Director Davidson Michael H.

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 518d
  SEC Form 4 filed by Director Garnier Jean Pierre

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 609d
  Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

  4/A - BioAge Labs, Inc. (0001709941) (Issuer)
• 609d
  Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 622d
  Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric

  4/A - BioAge Labs, Inc. (0001709941) (Issuer)
• 627d
  SEC Form 4 filed by Chief Medical Officer Rubin Paul D

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 627d
  SEC Form 4 filed by Chief Operating Officer Morgen Eric

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 627d
  SEC Form 4 filed by Chief Financial Officer Goldstein Dov A Md

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 627d
  SEC Form 4 filed by Chief Executive Officer Fortney Kristen

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 627d
  SEC Form 4 filed by Principal Accounting Officer Barton Shane

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 689d
  SEC Form 4 filed by Principal Accounting Officer Barton Shane

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 766d
  Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 769d
  Former 10% Owner Cormorant Asset Management, Lp converted options into 1,179,529 shares and bought $8,100,000 worth of shares (450,000 units at $18.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  Director Pande Vijay Satyanand converted options into 2,113,975 shares and bought $16,200,000 worth of shares (900,000 units at $18.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  Director Enright Patrick G converted options into 1,310,589 shares and bought $7,200,000 worth of shares (400,000 units at $18.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  SEC Form 4 filed by Chief Executive Officer Fortney Kristen

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  Director Healy James converted options into 1,638,236 shares and bought $11,999,970 worth of shares (666,665 units at $18.00) (SEC Form 4)

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  SEC Form 4 filed by Director Hemrajani Rekha

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  SEC Form 4 filed by Director Davidson Michael H.

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  SEC Form 4 filed by Director Garnier Jean Pierre

  4 - BioAge Labs, Inc. (0001709941) (Issuer)
• 773d
  SEC Form 4 filed by Chief Operating Officer Morgen Eric

  4 - BioAge Labs, Inc. (0001709941) (Issuer)